Investors focused on the Medical space have likely heard of The Ensign Group (ENSG - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
The Ensign Group is one of 899 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ENSG is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ENSG's full-year earnings has moved 9.60% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ENSG has returned 0.44% so far this year. Meanwhile, stocks in the Medical group have lost about 4.16% on average. As we can see, The Ensign Group is performing better than its sector in the calendar year.
Breaking things down more, ENSG is a member of the Medical - Nursing Homes industry, which includes 5 individual companies and currently sits at #12 in the Zacks Industry Rank. Stocks in this group have lost about 13.14% so far this year, so ENSG is performing better this group in terms of year-to-date returns.
ENSG will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of The Ensign Group (ENSG - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
The Ensign Group is one of 899 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. ENSG is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ENSG's full-year earnings has moved 9.60% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ENSG has returned 0.44% so far this year. Meanwhile, stocks in the Medical group have lost about 4.16% on average. As we can see, The Ensign Group is performing better than its sector in the calendar year.
Breaking things down more, ENSG is a member of the Medical - Nursing Homes industry, which includes 5 individual companies and currently sits at #12 in the Zacks Industry Rank. Stocks in this group have lost about 13.14% so far this year, so ENSG is performing better this group in terms of year-to-date returns.
ENSG will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on ENSG - FREE